N-terminal natriuretic propeptide type-b (NT-proBNP) and left ventricular ejection fraction in acute phase of st-segment elevation myocardial infarction and 1-year later
Abstract
Background: N-terminal natriuretic propeptide type-B (NT-proBNP) is a newer biochemical marker in acute coronary syndrome. NT-proBNP concentration of acute and chronic phase of STsegment elevation myocardial infarction is a predictor of ventricular function and prognosis.
Methods: In a sequence of 35 patients (22 men, 13 women, mean age 66.4 ± 9.6 years) with first STEMI an NT-proBNP plasma concentration and echocardiography was performed in acute phase and one year later. A comparison of NT-proBNP values of both phases was done. In addition, a correlation among NT-proBNP, ejection fraction (EF) and E/Em ratio was analysed.
Results: NT-proBNP concentration measured in STEMI acute phase was significantly higher in comparison with the value measured one year later (1833 pg/ml:419 pg/ml, p < 0.001). NT-proBNP was significantly higher in patients with anterior STEMI (n = 15) compared with the patients with inferior STEMI (n = 20) in acute phase and one year later. In patients with inferior STEMI a mean NT-proBNP value one year after infarction was below the limit values of 300 pg/ml (236 pg/ml). Between EF values in acute phase and one year later there was no significant difference (p = 0.667). 9 patients (26 %) had EF lower than 50 %. EF was significantly lower with anterior STEMI than with inferior one (p < 0.001). E/Em ratio betwen 2 groups showed no significant difference. A correlation between whole group NT-proBNP and ET was statistically insignificant and negative in STEMI acute phase (r = –0.526, p < 0.001) and one year later (r = –0.495, p < 0.003). Between NTproBNP and E/Em ratios no statistically significant difference was found. In subgroup of patients having E/Em ratio at one year greater than 10, NT-proBNP concentration was significantly higher in comparison with patients having E/Em lower than 10 (p < 0.001). A group of 8 patients with 3-vessel coronary artery disease (CAD) had significantly higher NT-proBNP one year after STEMI than a group of 15 patients with 1-vessel CAD (p < 0.001). EF values in both groups did not differ significantly.
Conclusions: A significant negative correlation between NT-proBNP and EF was proved. NT-proBNP concentrations in acute phase and one year later in patients with anterior STEMI were significantly higher from the ones in patients with inferior STEMI. One year after STEMI patients with 3-vessel coronary artery disease had a significantly higher NT-proBNP than patients with 1-vessel CAD. Increase ratio of NT-proBNP and coronarographic and echocardiographic data help in detection of patients with greater complication possibilities. For these patients, intense treatment, more accurate monitoring and more frequent follow-ups should be envisaged.
Downloads
References
Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 2003; 24: 1710–6.
Keber I. Natriuretični peptid BNP: pomen pri diagnozi, prognozi in zdravljenju srčnega popuščanja. In: Križman I (ed.). Interna medicina 2003; novosti in aktualnosti. Zbornik predavanj, Ljubljana, 3.–4. oktober 2003, 111–4.
Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92: 843–9.
Jug B, Šebeštjen M, Gajšek M, Corel D, Keber I. Diagnostic performance of NT-proBNP. In patients referred for specialised evaluation of signs and symptoms of heart failure. Slov Kardiol 2006; 2: 4–12.
Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28–66.
Omland T, Aakvaag A, Bonarjee VVS, Caidahl K, Nilsen DWT, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation 1996; 93: 1963–9.
Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921–9.
De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. Prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014–21.
Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786–92.
Heeschen C, Hamm CW, Mitrovic V, Lantelme N-H, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004; 110: 3206–12.
Mega JL, Morrow DA, De Lemos JA, Sabatine MS, Murphy SA, Rifai N, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol 2004; 44: 335–9.
Galvani M, Ottani F, Oltrona L, Ardissino D, Gensini GF, Maggioni AP, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 2004; 110: 128–34.
Björklund E, Jernberg T, Johanson P, Venge P, Dellborg M, Wallentin L, et al. Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction. Heart 2006; 92: 735–40
Vanderheyden M, Bartunek J, Goethals M. Brain and others natriuretic peptides: Molecular aspects. Eur J Heart Fail 2004; 6: 261–8.
Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6: 257–60.
Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82–91.
Talwar S, Squire IB, Downie PF, McCullough AM, Campton MC, Davies JE, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction. Correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21: 1512–21.
Arakawa N, Nakamura A, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology 1994; 85: 334–40.
Hillis GS, Ujino K, Sharon LM, Hagen ME, Oh JK. Echocardiographic indices of increased left ventricular filling pressure and dilatation after acute myocardial infarction. J Am Soc Echocardiogr 2006; 19: 450–6.
Blom J-R, van’t Hof AWJ, Henriques JPS, Geertman H, Slingerland R, Hoorntje CA. NT-proBNP: a marker for successful myocardial reperfusion in AMI patients treated with primary percutaneous coronary intervention. Eur J Heart Fail 2004; 6: 749– 52.
Omland T, Persson A, Ng L, O’Brien LR, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002; 106: 2913– 8.
Lang RM, Bierig M, Devereux RB, Flachskamp FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: areport from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a brannch of the European society of cardiology. J Am Soc Echocardiogr 2005; 18: 1449–63.
Waggoner AD, Bierig SM. Tissue doppler imaging: a useful echocardiographic method for the cardiac sonographer to assess systolic and diastolic ventricular function. J Am Soc Echocardiogr 2001; 14: 1143–52
Møller JE, Pellikka PA, Hillis GS, Oh JK. Prognostic importance of diastolic function and filling pressure in patients with acute myocardial infarction. Circulation 2006; 114: 438–44.
Tretjak M. Ocena polnilnega tlaka levega prekata s tkivno doplersko ehokardiografijo. Zdrav Vestn 2006; 75: 763–6.
Yu C-M, Sanderson JE, Marwick TH, Oh JK. Tissue doppler imaging. A new prognosticator for cardiovascular diseases. J Am Coll Cardiol 2007; 49: 1903–14.
Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, et al. National academy of clinical biochemistry laboratory medicine practice guidelines: Clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 2007; 115: e356–e375.
James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Arnstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A global utilization of strategies to open occluded arteries (GUSTO) – IV substudy. Circulation 2003; 108: 275–81.
Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 2003; 42: 1909–16.
Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005; 26: 241–9.
Lindahl B, Lindback J, Jerberg T, Johnston N, Stridsberg M, Venge P, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes. A Fragmin and fast revascularization during instability in coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol 2005; 45: 533–41.
Gill D, Seidler T, Troughton RW, Yandle TG, Frampton CM, Richards M, et al. Vigorous response in plasma N-terminal probrain natriuretic peptide (NT-BNP) to acute myocardial infarction. Clin Sci 2004; 106: 135–9.
Jernberg T, James S, Lindahl B, Stridsberg M, Venge P, Wallentin L. NT-proBNP in unstable coronary artery disease – experiences from the FAST, GUSTO IV and FRISC II trials. Eur J Heart Fail 2004; 6: 319–25.
Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ. Clinical utility of doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressures. A comparative simultaneous doppler – catheterization study. Circulation 2000; 102: 1788–94.
Dokainish H, Zoghbi WA, Lakkis NM, Al-Bakshy F, Dhir M, Quinones MA, et al. Optimal noninvasive assessment of left ventricular filling pressure. A comparison of tissue doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109: 2432–9.
Hillis GS, Møller JE, Pellikka PA, Gersh BJ, Wright S, Ommen SR, et al. Noninvasive estimation of left ventricular filling pressure by E/e is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol 2004; 43: 360–7.
Nilsson JC, Groenning BA, Nielsen G, Fritz-Hansen T, Trawinski J, Hildegrandt PR, et al. Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro-brain natriuretic peptide. Am Heart J 2002; 143: 696–702.
Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left ventricular remodeling after primary coronary angioplasty. Patterns of left ventricular dilatation and long-term prognostic implications. Circulation 2002; 106: 2351– 7.
Weber M, Dill T, Arnold R, Rau M, Ekinci O, Müller KD, et al. Nterminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004; 148: 612–20.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
